摘要
原文 | 英語 |
---|---|
文章編號 | 718380 |
期刊 | Evidence-based Complementary and Alternative Medicine |
卷 | 2013 |
DOIs | |
出版狀態 | 已發佈 - 2013 |
指紋
ASJC Scopus subject areas
- Complementary and alternative medicine
引用此文
Inhibition of metastatic potential in breast carcinoma in vivo and in vitro through targeting VEGFRs and FGFRs. / Chien, Ming Hsien; Lee, Liang Ming; Hsiao, Michael; Wei, Lin Hung; Chen, Chih Hau; Lai, Tsung Ching; Hua, Kuo Tai; Chen, Min Wei; Sun, Chung Ming; Kuo, Min Liang.
於: Evidence-based Complementary and Alternative Medicine, 卷 2013, 718380, 2013.研究成果: 雜誌貢獻 › 文章
}
TY - JOUR
T1 - Inhibition of metastatic potential in breast carcinoma in vivo and in vitro through targeting VEGFRs and FGFRs
AU - Chien, Ming Hsien
AU - Lee, Liang Ming
AU - Hsiao, Michael
AU - Wei, Lin Hung
AU - Chen, Chih Hau
AU - Lai, Tsung Ching
AU - Hua, Kuo Tai
AU - Chen, Min Wei
AU - Sun, Chung Ming
AU - Kuo, Min Liang
PY - 2013
Y1 - 2013
N2 - Angiogenesis and lymphangiogenesis are considered to play key roles in tumor metastasis. Targeting receptor tyrosine kinases essentially involved in the angiogenesis and lymphangiogenesis would theoretically prevent cancer metastasis. However, the optimal multikinase inhibitor for metastasis suppression has yet to be developed. In this study, we evaluated the effect of NSTPBP 0100194-A (194-A), a multikinase inhibitor of vascular endothelial growth factor receptors (VEGFRs)/fibroblast growth factor receptors (FGFRs), on lymphangiogenesis and angiogenesis in a mammary fat pad xenograft model of the highly invasive breast cancer cell line 4T1-Luc+. We investigated the biologic effect of 194-A on various invasive breast cancer cell lines as well as endothelial and lymphatic endothelial cells. Intriguingly, we found that 194-A drastically reduced the formation of lung, liver, and lymph node metastasis of 4T1-Luc+ and decreased primary tumor growth. This was associated with significant reductions in intratumoral lymphatic vessel length (LVL) and microvessel density (MVD). 194-A blocked VEGFRs mediated signaling on both endothelial and lymphatic endothelial cells. Moreover, 194-A significantly inhibited the invasive capacity induced by VEGF-C or FGF-2 in vitro in both 4T1 and MDA-MB231 cells. In conclusion, these experimental results demonstrate that simultaneous inhibition of VEGFRs/FGFRs kinases may be a promising strategy to prevent breast cancer metastasis.
AB - Angiogenesis and lymphangiogenesis are considered to play key roles in tumor metastasis. Targeting receptor tyrosine kinases essentially involved in the angiogenesis and lymphangiogenesis would theoretically prevent cancer metastasis. However, the optimal multikinase inhibitor for metastasis suppression has yet to be developed. In this study, we evaluated the effect of NSTPBP 0100194-A (194-A), a multikinase inhibitor of vascular endothelial growth factor receptors (VEGFRs)/fibroblast growth factor receptors (FGFRs), on lymphangiogenesis and angiogenesis in a mammary fat pad xenograft model of the highly invasive breast cancer cell line 4T1-Luc+. We investigated the biologic effect of 194-A on various invasive breast cancer cell lines as well as endothelial and lymphatic endothelial cells. Intriguingly, we found that 194-A drastically reduced the formation of lung, liver, and lymph node metastasis of 4T1-Luc+ and decreased primary tumor growth. This was associated with significant reductions in intratumoral lymphatic vessel length (LVL) and microvessel density (MVD). 194-A blocked VEGFRs mediated signaling on both endothelial and lymphatic endothelial cells. Moreover, 194-A significantly inhibited the invasive capacity induced by VEGF-C or FGF-2 in vitro in both 4T1 and MDA-MB231 cells. In conclusion, these experimental results demonstrate that simultaneous inhibition of VEGFRs/FGFRs kinases may be a promising strategy to prevent breast cancer metastasis.
UR - http://www.scopus.com/inward/record.url?scp=84879294018&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879294018&partnerID=8YFLogxK
U2 - 10.1155/2013/718380
DO - 10.1155/2013/718380
M3 - Article
C2 - 23861711
AN - SCOPUS:84879294018
VL - 2013
JO - Evidence-based Complementary and Alternative Medicine
JF - Evidence-based Complementary and Alternative Medicine
SN - 1741-427X
M1 - 718380
ER -